Will the EPO’s Enlarged Board of Appeal hear the Broad's CRISPR case?

Research output: Contribution to journalJournal articleResearchpeer-review

As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
Original languageEnglish
JournalLife Sciences Intellectual Property Review (LSIPR)
Issue number13/7 2018
Number of pages6
Publication statusPublished - 13 Jul 2018

    Research areas

  • Faculty of Law - patents gene editing, CRISPR-Cas 9, European Patent Office, Appeal, Broad Institute

ID: 199125991